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HYPERLIPIDEMIA
Low Density Lipoprotein Apheresis Improves Regional Myocardial
Perfusion in Patients With Hypercholesterolemia and Extensive
Coronary Artery Disease
The LDL-Apheresis Atherosclerosis Regression Study (LAARS)
WIM R. M. AENGEVAEREN, MD, ABRAHAM A. KROON, MD,
ANTON F. H. STALENHOEF, MD, PHD, GERARD J. H. UIJEN, PHD,
TJEERD VAN DER WERF, MD, PHD, FACC
Nijmegen, The Netherlands
Objectives. In a randomized study we evaluated the effect of
biweekly low density lipoprotein (LDL) apheresis plus simvastatin
versus medication alone on regional myocardial perfusion.
Background. In patients with severe hypercholesterolemia, diet
and lipid-lowering drugs are often insufﬁcient to achieve optimal
LDL cholesterol values. Low density lipoprotein apheresis is a
very effective lipid-lowering therapy. Assessment of regional myo-
cardial perfusion enables evaluation of the functional state of the
coronary circulation.
Methods. We studied 42 patients with severe hypercholesterol-
emia and extensive coronary artery disease who were randomized
to diet and simvastatin with or without biweekly LDL apheresis.
Regional myocardial perfusion was assessed by digital subtraction
angiography with videodensitometric calculation of hyperemic
mean transit time (HMTT) of contrast medium at baseline and
after 2 years of therapy.
Results. Low density lipoprotein cholesterol decreased by 63%
(to 3.0 mmol/liter) in the LDL apheresis group and by 47% (to
4.1 mmol/liter) in the medication group. Paired HMTT measure-
ments were assessed in 43 regions in the LDL apheresis group and
35 regions in the medication group. In the LDL apheresis group,
regional HMTT decreased over 2 years from 3.35  1.18 (mean 
SD) to 2.87  0.82 s (14%, p  0.001), whereas no change in the
medication group was observed: 2.95  1.06 to 2.96  0.90 s (p 
NS). In the patient-based comparison, the mean change in HMTT
was 0.45 s (14%, p  0.01) in the LDL apheresis group and
0.05 s (2%, p  NS) in the medication group, respectively.
Only exercise-induced ischemia improved in the LDL apheresis
group.
Conclusions. Biweekly LDL apheresis plus simvastatin decreased
time-averaged LDL cholesterol levels by an additional 31% (1.1
mmol/liter) compared with medication alone. After 2 years of ther-
apy, regional myocardial perfusion improved in the LDL apheresis
group and remained unchanged in the medication group. Thus,
aggressive reduction of LDL cholesterol has a favorable effect on
regional myocardial perfusion and alleviates ischemia.
(J Am Coll Cardiol 1996;28:1696–704)
1996 by the American College of Cardiology
Low density lipoprotein (LDL) cholesterol levels often remain
elevated in patients with familial hypercholesterolemia (FH)
despite diet and cholesterol-lowering drugs. High LDL choles-
terol levels are strongly associated with premature develop-
ment of coronary artery disease, especially in men with an
inherent risk of coronary death (1). Low density lipoprotein
apheresis is considered a valuable therapeutic option for
patients with homozygous FH and for patients with coronary
artery disease and hypercholesterolemia refractory to diet and
drugs (2–4). It has been shown in a number of nonrandomized
studies (2,5–8) that plasma exchange or LDL apheresis led to
regression or slowing of progression of coronary atheroscle-
rotic lesions and resolution of xanthomas. The use of plasma
exchange was also associated with increased survival among
patients with homozygous FH compared with their untreated
homozygous siblings (9). In one recently published randomized
trial in patients with FH (10), biweekly LDL apheresis versus
drug therapy for 2 years showed no difference in coronary
anatomy as measured by quantitative coronary angiography
(QCA) (10). In the LDL-Apheresis Atherosclerosis Regres-
sion Study (LAARS) (11), there was also no difference in
quantitatively assessed coronary anatomy, but patients under-
going LDL apheresis had a signiﬁcant improvement in exercise
variables versus patients on drug therapy alone. Questions
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remain about 1) the cause of this functional improvement, 2)
the methods for evaluating the potential beneﬁts in aggressive
lipid-lowering therapy, and 3) the impact on patient care.
Traditionally, clinical end points, such as improved survival
and reduction of major cardiac events, are the best proof of
effect in lipid-lowering trials but require numerous patients
over a long period of time (12,13). Quantitative coronary
angiography is the present reference standard for evaluating
lipid-lowering therapy in coronary artery disease (14–16).
However, application of QCA has several limitations, such as
the diffuse character of coronary artery disease, complexity of
stenosis geometry, foreshortening in nonorthogonal views,
insufﬁcient contrast staining and limited resolution of the
radiographic chain (16–18). Moreover, there seems to be a
dissociation between the results of angiographic studies and
clinical outcome. Lipid-lowering therapy reduces the incidence
of cardiovascular events to a greater extent than the propor-
tionate changes in plaque dimensions suggest (15,19). Reduc-
tion of hypercholesterolemia retards the progression of coro-
nary atherosclerosis by depleting the lipid core of the plaque
and deminishing the inﬂammatory process; not the change in
angiographic lumen size but the process of plaque stabilization
appears to decrease the risk of disruption with fewer clinical
events (20). The endothelium plays a major role in regulating
the vascular smooth muscle tone. Endothelial dysfunction can
result in an impaired blood ﬂow of the large and small
coronary arteries (21–25). Dysfunction of endothelium-
mediated vasomotion is associated with atherosclerosis, hyper-
cholesterolemia and smoking in adults and is already present
in the systemic arteries of children with heterozygous FH
(21–26). Lipid-lowering therapy improves the endothelium-
mediated vasomotion after relatively short periods of time
(27–29). The functional improvement of the coronary circula-
tion precedes structural improvement (30). The cumulative
effects of all anatomic and functional abnormalities of the
epicardial coronary arteries in combination with possible dys-
function of conduit and resistance vessels are responsible for
the ultimate effect of atherosclerosis on myocardial perfusion.
In this setting, it should be emphasized that minor changes in
lumen diameter of the coronary arteries have a major effect on
vascular resistance, according to Poisseuille’s law.
To evaluate the functional state of the coronary circulation
after aggressive lipid-lowering therapy with LDL apheresis, we
assessed regional myocardial perfusion by means of digital
subtraction angiography (DSA) followed by videodensitomet-
ric calculation of the hyperemic mean transit time (HMTT) of
contrast medium in the LAARS trial.
Methods
The purpose of the study was to compare the effects of
aggressive lipid-lowering treatment by LDL apheresis versus
conventional treatment on the anatomy and functional state of
the coronary tree. The trial design, patient characteristics,
methodology of lipid measurements, QCA and exercise testing
have been described previously (11). Brieﬂy, consenting pa-
tients with extensive coronary artery disease and hypercholes-
terolemia were randomized to diet and 40 mg of simvastatin
once daily with or without biweekly LDL apheresis. The
inclusion criteria were 1) male patients between 18 and 70
years old; 2) extensive coronary atherosclerosis demonstrated
by cardiac catheterization; 3) total serum cholesterol 8.0
mmol/liter or LDL cholesterol 5.8 mmol/liter and serum
triglycerides 5.0 mmol/liter during a standard lipid-lowering
diet. The ethics committee of the University Hospital of
Nijmegen approved the study. The study cohort included 42
male patients with a mean (SD) age of 52.0  9.2 years
(range 29 to 69). The elevated lipid levels were due to
heterozygous FH in 32 patients (76%), 16 in each group. In the
remaining 10 patients, the diagnosis was primary hypercholes-
terolemia in 8 (19%) and familial combined hypercholesterol-
emia in 2 (5%). In the LDL apheresis group, 17 patients had
three-vessel disease, and 4 had two-vessel disease, whereas in
the medication group 19 patients had three-vessel disease, and
2 had two-vessel disease (a vessel was considered diseased
when there was 50% diameter stenosis in a major branch).
Before entry into the study, all patients had a 2-month run-in
period. Antianginal medication was continued, but lipid-
lowering medication was stopped. If total cholesterol remained
elevated above the lower limit for inclusion into the study,
cardiac catheterization and exercise testing were carried out.
After cardiac catheterization, patients were randomized in a
stratiﬁed way, which took into account the total cholesterol
and lipoprotein(a) levels, age and history of coronary bypass
surgery. Antianginal medication was continued at the same
doses during the trial. If adaptation in medication was neces-
sary during the study, the original prescription, if possible, was
restored before the follow-up cardiac catheterization. The
follow-up cardiac catheterization was performed 1 month after
the last LDL apheresis. Low density lipoprotein apheresis was
performed with an automated system MA-01 (Kanegafuchi
Chemical Industry Co. Ltd, Osaka, Japan) with two small-sized
dextran sulfate cellulose columns that were used and regener-
ated alternately in one procedure, permitting continuous
apheresis (11). Before the start of the LDL apheresis, all
patients received 10,000 U of heparin. A volume of 5,000 ml
(1.5 plasma volume) was treated per session.
Abbreviations and Acronyms
DSA  digital subtraction angiography
FH  familial hypercholesterolemia
HMTT  hyperemic mean transit time (of contrast
medium)
LAARS  LDL-Apheresis Atherosclerosis Regression Study
LAD  left anterior descending coronary artery
LCx  left circumﬂex coronary artery
LDL  low density lipoprotein
QCA  quantitative coronary angiography
RCA  right coronary artery
ROI  region of interest
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Assessment of regional myocardial perfusion. We used the
method of DSA, followed by videodensitometry and calcula-
tion of the HMTT of contrast to compare the maximal regional
myocardial perfusion in the areas of the left anterior descend-
ing coronary artery (LAD), left circumﬂex coronary artery
(LCx) and right coronary artery (RCA) at baseline and at
follow-up. This method has been developed in our laboratory
and has been validated in model studies, animal experiments
and in humans (31–34). Before cardiac catheterization, pa-
tients were trained to hold their breath with use of a nose
clamp at maximal inspiration for 15 to 20 s. After completion
of angiography of the LAD, the left Judkins catheter with a 7F
tip (Cordis) was left in place for the DSA protocol, in which a
60 left anterior oblique projection was used. After angiogra-
phy of the RCA, the protocol was repeated in the 30 right
anterior oblique projection. Meticulous care was taken to
repeat the follow-up DSA under exactly the same circum-
stances, with the same medication.
At the start of the procedure, a 5F stimulation catheter was
positioned in the right atrium. During DSA, the heart was
triggered in synchrony with the radiographic pulses, slightly
above its inherent rate, to provide a strictly regular heart
rhythm. Iohexol-350 (Nycomed AS, Oslo, Norway), a nonionic
low osmolar contrast agent was used. For all studies, 6 ml of
contrast medium was injected, using a power injector at a
speed of 4 ml/s. Twenty-ﬁve seconds after administration of 8
to 12 mg of papaverine (depending on the size of the vascular
bed), the patient was instructed to hold his breath, and image
acquisition was started 5 s later followed by contrast injection.
One image/heart cycle was obtained just before the onset of
the QRS complex. Image acquisition was performed on a Bicor
radiograph system connected to a Digitron-3 computer for
digital subtraction angiography (Siemens AG, Erlangen, Ger-
many). Images were generated with the automatic brightness
control switched off after the fourth image in every study to
enable density calculation. Subsequently, the images were
digitized in a 512  512 matrix with 1,024 density levels. The
image quality was checked immediately after image acquisi-
tion, and if necessary the imaging protocol was repeated a
maximum of three times.
Image and data processing were performed off-line using a
Sun SPARC station 10 (Sun Microsystems, Inc.) with pro-
grammed Khoros software. Circular regions of interest (ROIs)
of 200 to 600 pixels were constructed over the tip of the
coronary catheter to record the contrast injection and over the
myocardium supplied by the respective vessels (Fig. 1). The
ROIs were chosen at the myocardial level on predeﬁned
localizations, carefully avoiding overlap with major side
branches and veins. Close to the myocardial ROI, a back-
ground ROI was chosen to analyze changes in background
density (Fig. 1). Time–density curves were generated by sam-
pling the averaged pixel density within a ROI in consecutive
images and, subsequently, these curves were ﬁtted with a
gamma-variate function. In case of deviating background den-
sity, the ﬁtted curves of the myocardial ROIs were corrected
with the corresponding background ROI. The HMTT is the
difference in the mean transit time of the contrast medium at
the myocardial ROI and at the injection site ROI (ROI at
catheter tip). Because of the pressure dependency of ﬂow
during maximal hyperemia, HMTTs were corrected for a
normalized mean aortic blood pressure of 100 mm Hg for
comparison between the two studies. This correction was
performed by multiplying the mean transit time in seconds by
the ratio Pa/100, where Pa is the actual mean blood pressure
during image acquisition. If a pressure curve showed a pressure
drop or wedging during hyperemia, indicating that the catheter
inﬂuenced maximal ﬂow, the study was excluded from further
analysis. Myocardial areas that were subjected to a Q wave
myocardial infarction or occlusion of the proximal vessel were
excluded from analysis.
For ﬁnal analysis, paired time–density curves of sufﬁcient
quality without artifacts were selected by a cardiologist
(W.R.M.A.) who had no knowledge of treatment allocation.
Figure 2 shows an example of paired time–density curves of an
ROI. The ﬁnal data base was composed, and subsequent
HMTTs were calculated and corrected for blood pressure, as
stated before. Regional myocardial perfusion was assessed by
averaging the comparative HMTTs (one to two ROIs) in the
area supplied by the LAD, LCx and RCA to one value/
perfusion area per session. Perfusion areas supplied by bypass
Figure 1. Example of the positioning
of the ROIs in one of the subtracted
images of the coronary arteries early
after contrast injection. Left panel,
LAD in the 60 left anterior oblique
projection. Right panel, RCA in the
30 right anterior oblique projection.
B  background ROI; C1,2  ROIs
1 and 2 in perfusion area of LCx;
L1,2  ROIs 1 and 2 in perfusion
area of LAD; P  ROI at catheter
tip; R1,2  ROIs 1 and 2 in perfu-
sion area of RCA.
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grafts were also imaged by the DSA protocol, carefully avoid-
ing evaluation of perfusion areas with competitive ﬂow
through native coronary artery and bypass graft. The ROIs of
perfusion areas supplied by bypass grafts were classiﬁed as part
of the original coronary artery region. Analysis of the effect of
both lipid-lowering treatments on myocardial perfusion was
calculated from HMTT values derived from individual ROIs
from a regional- and patient-based assessment of HMTT. The
patient-based evaluation was performed by averaging the
regional HMTT values to one value per patient as a global
estimate of myocardial perfusion. Analysis of the patient-based
HMTT values was performed both with and without correction
for change in hematocrit. For this correction the HMTT values
at follow-up were subtracted by the percent change in hemat-
ocrit, assuming a linear relation between hematocrit and blood
viscosity in this narrow range of actual hematocrit values (35).
Statistical analysis. Comparisons of prespeciﬁed continu-
ous variables within groups were made by two-sided paired t
tests and between-group analysis by unpaired t tests for
normally distributed data. For categoric comparison, a chi-
square test was performed when appropriate. Correlations
were tested with the Pearson correlation coefﬁcient. For all
hypothesis tests, a two-sided p value 0.05 was considered
signiﬁcant. Results are expressed as mean value  SD, unless
otherwise indicated.
Results
Forty-two male patients were randomized into two groups
of 21 patients in our center. The results in both groups for lipid
metabolism, QCA, exercise testing and clinical events have
been described elsewhere (11). In short, LDL cholesterol
decreased in the LDL apheresis group from 7.78  1.86
mmol/liter to a time-averaged value of 2.95  1.13 mmol/liter
and from 7.85  2.34 to 4.13  1.58 mmol/liter in the
medication group. Quantitative coronary angiography showed
no changes in mean segment diameter and minimal obstruc-
tion diameter within and between the two groups. At exercise
tests, in the LDL apheresis group versus the medication group,
time to onset of 1-mm (0.1 mV) ST segment depression was
prolonged by 39%, and maximal ST segment depression was
halved. Clinical characteristics and patient-based study data
are shown in Table 1.
Hyperemic mean transit time. The DSA protocol for cal-
culation of HMTT was performed in all 42 patients. In the
LDL apheresis group, 19 patients completed the 2 years of
LDL apheresis; 2 stopped because of progression of angina
pectoris after 3 and 10 months, respectively. Both patients
underwent coronary artery bypass graft surgery. In the medi-
cation group, one patient underwent bypass surgery after 22
months of treatment. The HMTT studies of these patients at
follow-up were considered as end of study measurements. One
patient in the LDL apheresis group who was admitted to the
hospital for unstable angina pectoris 12 months after the start
of the LDL apheresis underwent percutaneous transluminal
coronary angioplasty of the LAD and the RCA. After coronary
angioplasty, LDL apheresis was continued, but the two perfu-
sion areas were excluded from assessment of regional myocar-
dial perfusion. In 35 patients (83% [18 in the LDL apheresis
group, 17 in the medication group]), comparative data from
Figure 2. Example of paired time–density curves of ROI at
baseline (upper panel) and at follow-up (lower panel). The
HMTT values are calculated from these curves, where the
onset of time is derived from the time–density curve of
the respective ROI at the injection site (not shown).
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the ﬁrst study and subsequent follow-up were available. Paired
data were missing in seven patients because of 1) insufﬁcient
image quality from one session in two patients and from both
sessions in a third patient with chronic airway obstruction; 2)
loss of stored digital images from one session in two patients;
and 3) no comparable DSA in two patients.
Evaluation of myocardial perfusion based on individual
ROIs. In total, 121 comparative ROIs were available, 68 in the
LDL apheresis group and 53 in the medication group (mean
3.5 1.7/patient). One hundred three ROIs were generated in
regions supplied by native coronary arteries and 18 supplied by
bypass grafts. On the basis of the ROIs, the average HMTT
Table 1. Clinical Characteristics and Patient-Based Study Data
Pt No./Age (yr) Group
Prestudy
Event
LDL Chol (mmol/liter)
MSD
(mm)
MOD
(mm)
ST Time
(s)
HMTT
(s)Base During
1/29 L / 12.09 5.67 0.39 0.20 	420 0.17
2/59 M I/C 7.01 3.74 0.14 0.15 	0.09
3/67 M A/C 6.62 3.90 0.11 0.05 0 0.97
4/59 M I/ 7.05 4.26 0.06 0.04 1.46
5/52 M I/ 5.94 3.58 	0.14 	0.12 	1.58
6/43 L NQ/ 5.45 2.65 	0.30 	0.24 	30 	0.19
7/69 M I/CP 6.28 3.06 0.11 	0.09
8/67 M I/P 6.51 2.69 	0.42 	0.25 2.57
9/46 L / 6.63 3.00 	0.12 	0.09 	360 	0.62
10/65 L / 6.97 3.76 0.05 0.07 	0.14
11/46 L I/C 7.17 2.76 0.23 0.19
12/46 M A/ 6.11 3.57 	0.08 	0.08 60 	0.75
13/66 L I/ 6.97 2.14 	0.08 	0.16 	299
14/58 M /C 6.43 3.47 0.07 0.12
15/53 L I/C 6.80 1.98 	0.09 	0.14 	360 	0.38
16/40 M / 9.90 5.32 0.26 0.20 120 0.00
17/58 L I/C 6.71 2.03 0.00 	0.13 	60 	0.51
18/52 L A/C 11.36 5.22 	0.33 	0.06 23 	0.06
19/47 M I/C 12.86 5.62 	0.29 	0.09 	0.41
20/30 L A/C 10.75 3.69 	0.03 	0.06 	330 0.41
21/50 L A/C 7.60 3.12 0.04 0.20
22/45 M NQ/ 9.20 4.95 0.07 0.10 0 	0.21
23/56 M A/C 11.65 4.93 0.17 0.07 	0.62
24/44 M I/ 6.59 3.43 0.18 0.06 360 	0.14
25/57 L I/P 7.06 2.09 	0.02 	0.06 	165 	1.09
26/56 M I/C 5.92 2.76 0.08 0.05 	120 	1.58
27/50 L I/ 10.84 3.36 	0.06 	0.04 	0.30
28/42 L A/ 7.60 2.51 0.20 0.17 0.45
29/63* L IA/C 6.57 2.09 	1.27
30/49 M /CP 8.30 4.29 0.00 0.03 	1.50
31/52 M I/ 7.60 4.14 	0.01 0.02 60 0.22
32/54 L I/C 6.28 2.10 0.10 0.09 	240 	1.51
33/42 L / 7.03 2.00 	0.14 	0.11 	0.50
34/56 M A,A/C 6.68 3.26 	0.06 	0.08 0 0.59
35/56 L A/C 6.66 2.03 	0.11 	0.13 	55 	1.34
36/46 L / 8.84 4.02 0.00 0.03 	67 	0.36
37/49 M NQ/ 7.31 4.48 0.07 	0.01
38/50 M A/CP 5.83 2.79 0.24
39/62 L I/PC 6.36 2.59 	0.03 0.03 	60 	1.37
40/54 L I/ 6.38 2.27 0.03 	0.01 	88 0.57
41/66 M A/ 7.16 3.16 	0.02 	0.07 	60
42/42 M I/P 13.90 9.29 0.20 0.15 5 	0.03
*Patient underwent repeat coronary artery bypass graft surgery (C) 12 weeks after start of low density lipoprotein (LDL) apheresis and died postoperatively due
to low cardiac output. A  anterior myocardial infarction; Base  baseline; During  mean LDL cholesterol level during trial (for LDL apheresis group [L], data are
time-averaged values [for conversion to mg/dl, multiply by 38.7]); I  inferior myocardial infarction; M  medication; NQ  non-Q wave myocardial infarction; P 
percutaneous transluminal coronary angioplasty; Pt  patient; HMMT  change in hyperemic mean transit time; MOD  change in minimal obstruction diameter
(baseline vs. follow-up); MSD  change in mean segment diameter from quantitative coronary angioplasty measurements (baseline vs. follow-up); ST Time 
change in time to 1-mm (0.1 mV) ST segment depression.
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decreased by 0.59  1.01 s in the LDL apheresis group (p 
0.0001) and by 0.10 1.16 s (p 0.52) in the medication group
(0.48-s between-group difference, p  0.01).
Evaluation of regional myocardial perfusion (Table 2). Base-
line HMTT values for the LDL apheresis and medication
groups were 3.35  1.18 s (n  42) and 2.95  1.06 s (n  35),
respectively, and were statistically not different (p 0.52). The
relative changes in HMTT in the three perfusion areas of the
LAD, LCx and RCA are shown in Figure 3. All three coronary
perfusion areas in the LDL apheresis group contributed
equally to the ﬁnal result.
Patient-based analysis. In the patient-based analysis the
average HMTT value in the LDL apheresis group (n 18) was
3.19  0.78 s at baseline and 2.74  0.68 s at follow-up (mean
difference	0.45 s [	14%], p 0.01). In the medication group
(n  17), the average HMTT value was 2.99  0.84 s at
baseline and 2.94  0.77 s at follow-up (mean difference
	0.05 s [	2%], p  0.85), for a mean difference in change
between the two groups of 0.40 s (p  0.19).
Hematocrit measured at cardiac catheterization in the LDL
apheresis group was 0.44  0.03 at baseline and 0.43 
0.04 liter/liter at follow-up (p  0.23) and 0.45  0.03 and
0.45  0.03 liter/liter, respectively, in the medication group
(p  0.44). For correction of possible changes in blood
viscosity due to changes in hematocrit, the mean patient-based
HMTT at follow-up catheterization was corrected by the
percent change in hematocrit from baseline to follow-up
catheterization. In the LDL apheresis group (n  18), the
average HMTT corrected for hematocrit change decreased
from 3.19 0.78 s at baseline to 2.78 0.69 s at follow-up (p
0.008) and from 2.99  0.84 s at baseline to 2.97  0.84 s at
follow-up in the medication group (p  0.94). The mean
difference in HMTT between the LDL apheresis group and the
medication group after correction for hematocrit was 0.38 s
(p 0.22), rather than 0.40 s without correction for hematocrit
changes.
There were no signiﬁcant correlations between the change
in percent as well as absolute changes in HMTT with the mean
lipid levels during the trial [total cholesterol, LDL cholesterol,
high density lipoprotein cholesterol, ratio of LDL to high
density lipoprotein cholesterol, lipoprotein(a)] or relative and
absolute changes in lipid levels. No signiﬁcant correlations
were found between percent changes as well as absolute
changes in HMTT and minimal obstruction diameter, mean
segment diameter and time to 1-mm ST segment depression.
Classiﬁcation of the patients into two groups (improvement vs.
no change in or impairment of time to 1-mm ST segment
depression at exercise test) showed a decrease in HMTT of
16 21% in the group with improvement versus an increase in
HMTT of 4 19% in the group with no change or impairment
(p 0.04). The change in hematocrit at cardiac catheterization
was not related to the time to 1-mm ST segment depression or
to the change in HMTT.
Discussion
Although the LAARS trial showed no signiﬁcant change in
quantitatively assessed coronary anatomy in both groups, the
results of the HMTT measurements showed an increase in
myocardial perfusion in the LDL apheresis group, whereas the
medication-only group remained in stable condition. This
improvement in myocardial perfusion in the LDL apheresis
group is in agreement with the improved ischemic threshold
that has been previously reported (11,36). These results show
a discrepancy between anatomic and physiologic variables in
the assessment of coronary atherosclerosis. The improved
functional status in the LDL apheresis group was accompanied
by a lower LDL cholesterol level (1.1 mmol/liter) than in the
medication-only group. To explain the improvement in myo-
cardial perfusion, we hypothesized that one or more of the
following mechanisms may be operative:
1. Recovery of endothelial nitric oxide production and release
in the conduit vessels. Recent studies in animals and humans
(21–25,37) associate hypercholesterolemia and increased
Lp(a) levels with impaired endothelium-dependent vasodila-
tion. Lipid lowering during 6 months to 1 year may enhance
endothelial function, as assessed with acetylcholine (27–29).
Improvement in endothelial function may enhance exercise-
Figure 3. Bar graphs showing mean percent change in HMTT  SEM
in the regions of the LAD, LCx (ramus circumﬂexus [RCX]) and RCA,
respectively, for the LDL apheresis group versus the medication group.
Table 2. Regional Hyperemic Mean Transit Time Values in the
Three Myocardial Perfusion Areas
LAD
Region
LCx
Region
RCA
Region
All
Regions
LDL apheresis group n  17 n  18 n  7 n  42
Baseline HMTT (s) 3.28 (0.97) 2.93 (0.66) 4.61 (1.85) 3.35 (1.18)
Follow-up HMTT (s) 2.81 (0.86) 2.66 (0.67) 3.57 (0.79) 2.87 (0.82)
p value 0.02 0.08 0.11 0.001
Medication group n  15 n  13 n  7 n  35
Baseline HMTT (s) 2.78 (0.78) 3.15 (1.22) 2.95 (1.35) 2.95 (1.06)
Follow-up HMTT (s) 2.75 (0.81) 3.11 (1.07) 3.14 (0.79) 2.96 (0.90)
p value 0.88 0.93 0.74 0.96
Difference (p value)* 0.17 0.51 0.14 0.04
*Difference in mean change between low density lipoprotein apheresis and
medication group (t test). Data presented are mean value (SD). HMTT 
hyperemic mean transit time; LAD  left anterior descending coronary artery;
LCx  left circumﬂex coronary artery; RCA  right coronary artery.
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induced dilation of the large epicardial coronary arteries
(21,38). Short-term cholesterol lowering with LDL apheresis
directly improves endothelium-dependent relaxation of the
epicardial coronary arteries, suggesting a direct effect of LDL
cholesterol (39). The more pronounced lipid lowering in the
LDL apheresis group in this study may result in better recovery
of endothelial function and may thus improve the ischemic
threshold at exercise testing. Assessment of HMTT reveals a
time variable that is inversely related to maximal myocardial
perfusion. Because of the method of assessment of HMTT
(intracoronary papaverine and sublingual isosorbide dinitrate),
it is unlikely that endothelium-dependent vasodilation is in-
volved in the improved regional myocardial perfusion observed
in this study.
2. Remodeling of the conduit vessel wall. Progression or
regression of coronary artery stenosis may be associated with
complex shape changes or remodeling (40), in which the
integrated hemodynamic effects on the coronary circulation
may differ from the changes in minimal obstruction diameter
and mean segment diameter. According to Glagov et al. (41)
and Stiel et al. (42), progression of coronary artery disease
leads initially to compensatory dilation. In the setting of
regression of atherosclerotic plaques, this process might be
reversed, with remodeling of the vessel wall without a signiﬁ-
cant effect on lumen cross-sectional area of the epicardial
coronary arteries. However, the dilation of the remodeled
coronary arteries in response to papaverine may be enhanced,
and maximal myocardial perfusion may be increased. This view
is supported by a recent publication (43) in which the epicar-
dial response to intracoronary nitroglycerin administration
decreased signiﬁcantly with increasing atherosclerotic wall
thickening. Next to obstruction of the vascular lumen, athero-
sclerosis of the arterial wall also has an endothelium-
independent effect on coronary vasomotion and ﬂow. Decrease
in atherosclerotic thickening of the arterial wall without a
direct effect on the lumen size of the vessel may explain the
observation that functional improvement precedes anatomic
regression of atherosclerosis.
3. Improved arteriolar vasodilation. Resistance vessels are
spared from the development of overt atherosclerosis. How-
ever, relaxation of these vessels may be reduced in patients
with high LDL cholesterol levels due to alterations in endo-
thelial cell function, as established in primates (23).
Endothelium-dependent arteriolar relaxation was impaired,
whereas endothelium-independent responses were nearly
identical (23). In the human forearm model, the impairment of
microvascular vasodilator function in patients with hypercho-
lesterolemia is endothelium-dependent only (25); thus, im-
provement in endothelium-independent arteriolar vasodilation
as a mechanism for our results is highly speculative. Another
hypothesis, introduced by Gould et al. (44), is that the coronary
ﬂow response induced by direct effect of an arteriolar vasodi-
lator may be augmented by further improvement in ﬂow-
mediated, endothelium-dependent epicardial coronary artery
vasodilation. However, this effect was not likely to occur in this
study, where patients received isosorbide dinitrate for epicar-
dial coronary artery vasodilation before angiography. Maximal
epicardial vasodilation after sublingual isosorbide dinitrate is
known (45,46) to persist for 30 to 60 min, which was the time
needed in this study to perform angiography and DSA.
4. Changes in blood rheology. Improved myocardial perfu-
sion might be due to changes in blood rheology as a result of
repeated LDL apheresis (47,48). Because of this observation,
assessment of HMTT in the present study was performed 1
month after ﬁnal LDL apheresis to avoid a direct effect of LDL
apheresis on viscosity. In LDL apheresis over dextran sulfate
cellulose columns, plasma ﬁbrinogen, a determinant of viscos-
ity, is lowered acutely by 26% to 35%, returning to pretreat-
ment levels between 2 and 7 days (11,49). Seven days after
LDL apheresis plasma viscosity is unchanged, but blood vis-
cosity is still reduced, independent of the change in hematocrit
(48). Rigidity of red blood cells is increased in patients with
high LDL cholesterol values, causing elevated blood viscosity.
Low density lipoprotein apheresis improves the erythrocyte
deformability, but how long this effect lasts after multiple
procedures is unknown. In the study of Rubba et al. (48), 3
weeks after the last of six procedures for LDL apheresis, peak
blood ﬂow in the leg was signiﬁcantly increased, whereas that
in the forearm was unchanged. During our study, there was a
small decrease in hematocrit in the LDL apheresis group, but
at cardiac catheterization the hematocrit levels were not
signiﬁcantly different within and between both groups. The
results of HMTT analysis after correction for change in
hematocrit were virtually unchanged; we therefore decided to
use the original data set for the entire analysis.
In our opinion, two of the four potential mechanisms are
the most attractive explanations for the improved myocardial
perfusion in the LDL apheresis group. 1) The concept of the
remodeling of the vessel wall. It is conceivable that although
lumen dimensions have not (yet) changed signiﬁcantly, the
total atherosclerotic burden of the vessel wall has decreased
(“reversed Glagov sequence”), conditioning the vessel wall for
an increased response to a muscle relaxant such as papaverine.
In our study, lumen dimensions were assessed after adminis-
tration of isosorbide dinitrate but without papaverine, whereas
HMTT measurements were performed both after isosorbide
dinitrate and papaverine. 2) The improved rheologic condition
caused by LDL apheresis. The circumstantial evidence that
viscosity remained unchanged between baseline and follow-up
catheterization because of unchanged hematocrit and un-
changed ﬁbrinogen might be insufﬁcient. Whole-blood viscos-
ity is determined by many other factors, such as erythrocyte
deformability and triglyceride and total cholesterol levels.
Decreased whole-blood viscosity might have contributed to the
improved maximal myocardial perfusion.
Further lipid-lowering studies should use intracoronary
echocardiography to evaluate the total atherosclerotic burden
and the existence of a “reversed Glagov sequence,” combined
with analysis of the vascular reaction to papaverine. Further-
more, analysis of whole-blood viscosity is needed to under-
stand the basic interactions between lipid-lowering, viscosity,
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endothelium-dependent and endothelium-independent vascu-
lar responses and myocardial perfusion.
Limitations of the study. The HMTT is inversely related to
ﬂow if the vascular volume remains constant: t  V/F, where
t  mean transit time; F  ﬂow; and V  vascular volume
between the site of injection and point of measurement.
Assessment of HMTT was based on the assumption that
vascular volume after intracoronary papaverine administration
was maximal and equal at baseline and follow-up cardiac
catheterization. Theoretically, if vascular volume were smaller
because of atherosclerosis and ﬂow remained the same, a
shorter mean transit time could also be found that erroneously
could be interpreted as favorable. This type of error is very
unlikely because vascular volume is mainly determined by
arterioles and capillaries, vessels that are not involved in the
atherosclerotic process. In addition, the unchanged mean
segment diameter in this study supports the assumption that
the vascular volume of the conduit vessels remained un-
changed.
In this study, regional myocardial perfusion was assessed as
the primary end point for ﬂow evaluation. For patient-based
HMTT values, regions from one patient were averaged to one
HMTT value. However, in some patients only one region was
available; in one patient even based on only one ROI. In the
other patients, eight ROIs in three myocardial perfusion areas
were available (including bypass evaluation). Therefore,
patient-based HMTT values are not always representative of
the entire myocardial perfusion in that patient.
Conclusions. Biweekly LDL apheresis plus simvastatin im-
proved regional myocardial perfusion in patients with severe
hypercholesterolemia and extensive coronary artery disease. In
the control group, treated with lipid-lowering drugs only,
regional myocardial perfusion remained stable. The improve-
ment in myocardial perfusion is in agreement with that in
ischemic threshold at exercise testing. The additional decrease
in LDL cholesterol levels from LDL apheresis may be one
explanation for the functional improvement in coronary circu-
lation, although rheologic changes cannot be ruled out. Func-
tional improvement may be due to endothelium-dependent or
endothelium-independent changes, or both, in the coronary
circulation. Further studies will be needed for elucidation of
the exact mechanism. Calculation of the regional myocardial
perfusion by DSA with videodensitometric calculation of the
HMTT is feasible for evaluation of lipid-lowering trials. This
method requires some minor modiﬁcations of the radiographic
equipment and intensive instructions for the patient for breath
holding. Assessment of regional myocardial perfusion in lipid-
lowering studies has the beneﬁt of combined evaluation of the
epicardial coronary tree as well as the microcirculation.
We thank D. Kampschreur and the nursing staff of the cardiac catheterization
unit for their excellent assistance during cardiac catheterization and T. Pijnen-
burg for help with the processing and analysis of the DSA studies.
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